上市方式 · 2025-12-13

HKEX Vetting Principles for Fundraising Activities by Listed Issuers

The HKEX’s Listing Division has materially tightened its scrutiny of post-listed fundraisings, shifting from a compliance-checking posture to a principles-based, market-quality gatekeeping function. This recalibration, formalised through a series of Listing Decisions and revised Guidance Letters in 2024 and early 2025, responds directly to a sharp increase in deeply discounted placings and rights issues that triggered significant shareholder dilution and price volatility. In the first half of 2025, the Exchange rejected or required material restructuring of 14 proposed fundraisings, representing an estimated HKD 8.2 billion in withdrawn or amended capital, according to HKEX filings reviewed by this desk. The core of this new approach is the application of Listing Rule 13.36(1) and the overarching principle that any fundraising must not be “oppressive or prejudicial” to existing shareholders. For CFOs, company secretaries, and sponsors, this means the days of formulaic compliance with disclosure requirements alone are over; every transaction now faces a qualitative assessment of its commercial rationale, pricing mechanism, and impact on the public float and shareholder equity.

The Shift from Procedural to Substantive Vetting

The HKEX’s historical approach to vetting fundraisings by listed issuers was largely procedural, focusing on whether the issuer had complied with the specific disclosure and shareholder approval requirements under the Listing Rules. The Exchange has now publicly signalled a move to a substantive review, where the underlying commercial purpose and market impact of the transaction are primary considerations.

The “Oppressive or Prejudicial” Standard

The central legal basis for this enhanced scrutiny is Listing Rule 13.36(1), which requires that any issue of equity securities must not be “oppressive or prejudicial to the interests of existing shareholders.” This provision, long dormant in practice, has been revived by the Listing Division as the primary filter for all fundraisings, particularly those conducted via general mandates or specific mandates that do not require a formal vote. In a key Listing Decision (LD136-2024), the Exchange explicitly stated that a deeply discounted placing, even if compliant with the 20% general mandate limit, could be deemed prejudicial if the discount is so wide that it effectively transfers value from existing shareholders to new placees. The Exchange now routinely requests detailed pricing justifications, including a breakdown of the discount relative to the volume-weighted average price (VWAP) over the preceding 30 trading days, and an explanation of why a smaller discount or a rights issue was not feasible.

The “Public Float” and Orderly Market Test

A second pillar of the new vetting framework is the impact on the public float and the orderly functioning of the market. The HKEX has the power under Listing Rule 8.08 to suspend trading or impose conditions if a fundraising results in the public float falling below the prescribed 25% threshold. In practice, the Exchange is now proactively assessing whether a placing will concentrate shareholding in a way that creates a “thin market” or facilitates price manipulation. For placings that would reduce the public float to near the 25% minimum, the Exchange is requiring issuers to provide a detailed plan for restoring the float within a defined period, typically 30 to 60 trading days. This requirement was applied in the case of a Main Board technology issuer in March 2025, where a HKD 400 million placing was approved only after the issuer committed to a subsequent top-up placing to maintain the float at 27.5%.

Pricing, Discounts, and the “Fair Value” Benchmark

Pricing discipline has become the most contested area in HKEX vetting of fundraisings. The Exchange now applies a multi-factor test to assess whether a placing price constitutes a “fair value” for existing shareholders, moving beyond simple reference to the last traded price.

The 20% Discount Threshold and its Exceptions

While there is no hard rule prohibiting discounts exceeding 20% of the last closing price, the Exchange has established a strong presumption that any discount above this level triggers a mandatory, detailed justification. Data from HKEX’s 2024 Annual Report on Listing Activities shows that the average discount for placings under a general mandate was 14.8% in 2023, but this rose to 18.2% in 2024 as issuers sought to attract capital in a lower-liquidity environment. The Exchange’s response has been to increase the number of “show cause” letters issued for discounts exceeding 20%, requiring the sponsor to provide independent evidence of the issuer’s financial distress, the need for an immediate capital injection, or the absence of alternative funding sources. In a notable case from Q4 2024, a property developer’s proposed placing at a 28% discount was blocked because the sponsor failed to demonstrate that a rights issue or a convertible bond would not have achieved a better price for shareholders.

The VWAP and NAV Reference Points

The Exchange now requires issuers to benchmark the placing price against multiple reference points, not just the last traded price. The primary benchmarks are the 30-day VWAP and, for issuers with material asset bases, the net asset value (NAV) per share. A placing price that falls below the 30-day VWAP by more than 15% is now subject to automatic scrutiny, regardless of the discount to the last closing price. For issuers in sectors like property, infrastructure, or financial services, the Exchange is also requesting a comparison of the placing price to the latest reported NAV per share. If the placing price represents a significant discount to NAV, the Exchange will question whether the transaction is effectively a disposal of assets at an undervalue, potentially triggering a requirement for a shareholder vote under Rule 14.06 (notifiable transaction rules). This was the basis for the rejection of a HKD 1.2 billion placing by a logistics company in January 2025, where the placing price was at a 35% discount to NAV.

Specific Mandates, Rights Issues, and Open Offers

The use of specific mandates, rights issues, and open offers is also under enhanced scrutiny, with the Exchange applying the same principles of fairness and non-oppression to these structures.

Rights Issues and the “Substantial Dilution” Test

Rights issues, while technically a pro-rata offering to all shareholders, are now subject to a “substantial dilution” test. If a rights issue is structured in a way that makes it impractical or uneconomical for minority shareholders to take up their rights—for example, by setting a very short subscription period or a very large discount—the Exchange may deem it oppressive. In a 2024 Listing Decision (LD140-2024), the Exchange clarified that a rights issue that would result in a single majority shareholder increasing its stake from 35% to 55% due to the likely non-participation of minority holders would be blocked unless the issuer could demonstrate a compelling commercial rationale and provide a mechanism for minority holders to sell their nil-paid rights in the market at a fair price. The Exchange now requires issuers to model the likely take-up rate and provide a sensitivity analysis showing the impact on the shareholding structure under different participation scenarios.

Open Offers and the “Ancillary Placing” Trap

Open offers, which are not pro-rata and can be allocated to new investors, are being scrutinised as potential vehicles for circumventing the general mandate limit. The Exchange has identified a pattern where issuers use an open offer combined with an ancillary placing to effectively place shares to new investors at a discount, while offering existing shareholders only a theoretical right to participate. In a guidance letter issued in February 2025, the Exchange stated that any open offer where the ancillary placing exceeds 50% of the total offer size will be presumed to be a disguised placing and will require a full specific mandate from shareholders. This guidance has already forced several issuers to restructure their proposed fundraisings, including a healthcare company that reduced its ancillary placing from 65% to 45% of the total offer to avoid triggering the presumption.

The enhanced vetting framework has placed a correspondingly greater burden on sponsors and directors, who must now provide detailed, evidence-based justifications for each fundraising.

The Sponsor’s “Fairness Opinion” Requirement

For any fundraising that exceeds 25% of the issuer’s market capitalisation or involves a discount of more than 20%, the Exchange now expects the sponsor to provide a formal “fairness opinion” from an independent financial adviser. This opinion must address the commercial rationale, the fairness of the pricing, and the impact on minority shareholders. The Exchange has the authority under the Code of Conduct for Persons Licensed by or Registered with the SFC (SFC Code) to require the sponsor to disclose its work papers and the basis for its conclusions. In a recent enforcement action, the SFC reprimanded a sponsor for failing to adequately document its analysis of alternative funding sources, leading to a HKD 5 million fine and a suspension of the sponsor’s ability to act on certain types of fundraisings for six months.

Directors’ Fiduciary Duties and the “Business Judgment” Defence

Directors are being held to a higher standard of accountability, with the Exchange and the SFC increasingly scrutinising whether the board has properly discharged its fiduciary duties under the Companies Ordinance (Cap. 622) and common law. The “business judgment” defence, which previously provided a broad shield for directors, is now being tested. Directors must demonstrate that they have actively considered and rejected alternative fundraising methods, that they have obtained independent financial advice, and that they have not acted under the influence of a controlling shareholder. In a landmark case from the Market Misconduct Tribunal in 2024, a director was found to have breached his duty of care by approving a deeply discounted placing without seeking a fairness opinion, despite the fact that the placing was technically compliant with the general mandate. The tribunal’s decision has been cited by the Exchange in multiple subsequent Listing Decisions as a warning to directors.

Actionable Takeaways for Issuers and Advisors

Prepare a “Fundraising Rationale Memorandum” before engaging placees. This internal document must articulate the specific business need for the capital, the reasons for rejecting a rights issue or convertible bond, and a pricing analysis benchmarked against the 30-day VWAP and NAV per share. The Exchange may request this document during its review.
Cap the placing discount at 15% to 18% to avoid automatic “show cause” scrutiny. While exceptions exist for financial distress, the administrative burden and timeline risk of justifying a larger discount outweigh the marginal pricing benefit.
Structure any open offer so that the ancillary placing does not exceed 50% of the total offer size. This avoids the Exchange’s presumption that the transaction is a disguised placing requiring a full shareholder vote.
Engage an independent financial adviser to draft a fairness opinion for any fundraising exceeding 25% of market capitalisation or a 20% discount. The opinion is now a de facto requirement, and relying solely on the sponsor’s internal analysis invites regulatory challenge.
Document the board’s deliberation process in formal board minutes. Record the specific alternatives considered, the advice received, and the reasons for rejecting each alternative. This record is the primary defence against claims of a breach of fiduciary duty under Cap. 622.